Detail akcie Futura Medical online

Business Summary: Futura Medical plc is a United Kingdom-based pharmaceutical company that develops products for consumer healthcare. The Company is engaged in the research and development of pharmaceutical drugs and medical devices and the commercial exploitation. It is also engaged in transdermal delivery and has developed a transdermal technology, DermaSys for the absorption of active molecules through the skin. It specializes in sexual health and pain relief, and has approximately five products in its development pipeline, which include CSD500, MED2002, TPR100, TIB200 and SPR300. Its CSD500 product incorporates an erectogenic gel (known as Zanifil gel) to help men maintain a firmer erection during intercourse whilst wearing a condom. Its MED2002 is a gel applied directly to the penis for the treatment of male erectile dysfunction (ED). The Company's TPR100 is a gel to provide pain relief. Its SPR300 is a gel, which combines methyl salicylate and menthol with the DermaSys delivery system.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2018, Futura Medical plc. revenues decreased from L363K to L0K. Net loss increased 51% to L5.9M. Revenues reflect Europe segment decrease from L350K to L0K, Middle East segment decrease from L13K to L0K. Higher net loss reflects Research and development costs increase of 47% to L6M (expense), Administrative costs increase of 10% to L1.2M (expense).